massive potential small cap bio with cashflow, page-2

The current application for approval of the HepaFat-Scan technology due for aopproval in the 1st quarter of next year is a non-invasive method using a MRI scan and RHT's technology to determine the level of fat on the liver which will help doctors/sergurns better understand what they are dealing with and the most approrate steps foward.

An accurate assessment of liver fat could affect patient selection criteria and the surgeons approach to liver resection, improving the outcome for liver cancer patients

Pharmaceutical companies need an accurate non-invasive tool to measure liver fat in clinical trials for drugs in development which this new HepaFat-scan provides.

Appox 30% of the US population has some form a fatty liver disease. With the use of RHT's technology it will help doctors and sergeons find the most effective and appropiate approach to their patients in a non-invasive manner saving people from having un-needed sergery or sergery much sooner then needed had they not used the Hepi-Fat Scan technology.